Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Nutriband Inc. - Common Stock (NQ:NTRB)

5.500 -0.140 (-2.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nutriband Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Nutriband Receives Notice of Allowance for U.S. Patent Covering Transdermal Abuse Deterrent Technology
Via ACCESSWIRE
Nutriband Inc. (NASDAQ: NTRB) Near the Top of Equities by Percentage Gain on 5/31
Via Investor Brand Network
News headline image
Nutriband Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Nutriband Inc. Commences Trading on Upstream Under NTRB
Via ACCESSWIRE
News headline image
Nutriband Inc. Will Be the First Company to Dual List on Upstream
Via ACCESSWIRE
News headline image
Nutriband to Attend 2023 BIO International Convention
Via ACCESSWIRE
News headline image
Nutriband Inc. Reports Revenue Up 46% in Fiscal 2023
Via ACCESSWIRE
News headline image
Nutriband Inc. to Present at the Planet MicroCap Showcase: VEGAS 2023 on Wednesday, April 26, 2023
Via ACCESSWIRE
News headline image
Nutriband With Kindeva Drug Delivery Select Aversa(TM) Fentanyl Abuse Deterrent Formulation for Commercial Scale Manufacturing Process Development
Via ACCESSWIRE
News headline image
Nutriband Secures $2 Million Line of Credit Financing Facility to be Used for Commercialization of AVERSA(TM) Abuse-Deterrent Transdermal Technology
Via ACCESSWIRE
News headline image
Nutriband Approved for Dual Listing on Upstream
Via ACCESSWIRE
News headline image
Nutriband Supports Newly Published CDC Opioid Prescribing Guidelines
Via ACCESSWIRE
News headline image
Nutriband Inc Joins Webull Corporate Communications Service Platform
Via ACCESSWIRE
News headline image
Nutriband COO Alan Smith Ph.D. Selected for FDA Center for Research on Complex Generics Stakeholder Expert Committee
Via ACCESSWIRE
News headline image
Nutriband Inc. to File for Product Distribution Permit in South America with Ecuador's Health Register
Via ACCESSWIRE
News headline image
Nutriband Inc. to Present at the 2023 Transdermal and Microneedle Conference
Via ACCESSWIRE
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Begins New Year by Trading on Upstream
Via Investor Brand Network
InvestorNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Starts Trading on Upstream
Via Investor Brand Network
News headline image
Nutriband Inc. to Officially Launch AI Tape brand in Q1 2023
Via ACCESSWIRE
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Approval to Dual List, to Commence Trading on Upstream
Via Investor Brand Network
News headline image
Nutriband Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
Via ACCESSWIRE
News headline image
Nutriband Inc. Reports Record Revenue Up 118% YoY in Q3
Via ACCESSWIRE
News headline image
Nutriband Inc to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
Via ACCESSWIRE
News headline image
Nutriband Receives Notice of Issuance from the Canadian Intellectual Property Office for its AVERSA(TM) Abuse Deterrent Transdermal Technology Patent
Via ACCESSWIRE
News headline image
Nutriband To Manufacture Fleur Marché-Branded CBD Wellness Patches ↗
Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), has signed an exclusive manufacturing agreement with Fleur Marché for its CBD and Botanical Patch lines. 
Via Benzinga
News headline image
Nutriband Inc. to Manufacture Fleur Marché-branded Wellness Patches Under Exclusive Agreement
Via ACCESSWIRE
News headline image
Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on Lymphatic Etanercept Delivery in Rheumatoid Arthritis Patients With Results To Be Presented at the 2022 American College of Rheumatology
Via ACCESSWIRE
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.